Advertisement
Australia markets closed

  • ALL ORDS

    8,039.90
    +27.80 (+0.35%)
     

  • ASX 200

    7,796.00
    +26.60 (+0.34%)
     

  • AUD/USD

    0.6643
    -0.0015 (-0.23%)
     

  • OIL

    82.34
    +0.17 (+0.21%)
     

  • GOLD

    2,334.70
    -34.30 (-1.45%)
     

  • Bitcoin AUD

    96,880.36
    +445.84 (+0.46%)
     

  • CMC Crypto 200

    1,351.26
    -9.07 (-0.67%)
     

  • AUD/EUR

    0.6209
    -0.0008 (-0.13%)
     

  • AUD/NZD

    1.0849
    -0.0024 (-0.22%)
     

  • NZX 50

    11,682.39
    -89.42 (-0.76%)
     

  • NASDAQ

    19,700.43
    -51.87 (-0.26%)
     

  • FTSE

    8,237.72
    -34.74 (-0.42%)
     

  • Dow Jones

    39,150.33
    +15.57 (+0.04%)
     

  • DAX

    18,163.52
    -90.66 (-0.50%)
     

  • Hang Seng

    18,028.52
    -306.80 (-1.67%)
     

  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

BridgeBio Pharma, Inc.
·1-min read
BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc.

PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT.

To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220